anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

27 Cost Of Inaction

Loop collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 31,900
Current window 19,981-20,010
Pages 1,064
Rows per page 30
Loop: 27 Cost Of Inactionclear collectionreset all
18 30 60

Loop

19,981-20,010 of 31,900

filter-aware
09
The slide uses a list of icons to represent key clinical attributes of the drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · CompetitionLoop · Cost Of Inaction1 hit
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses dot plots for IC50 data and a bar chart for in vivo efficacy, highlighting NVL-520's performance.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
14
The slide uses two distinct chart types to demonstrate efficacy: a bar chart for brain penetrance and a grouped bar chart for selectivity index.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
17
Data table showing demographics, tumor types, ECOG performance status, and prior treatment history including specific TKI therapies.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
19
The chart displays dose-dependent exposure levels exceeding multiple target thresholds for ROS1 variants in CNS and periphery.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
20
Clinical trial data table showing efficacy metrics for a drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
22
The chart is a swimmer plot, commonly used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
Includes MRI scan series showing lesion reduction over 8 weeks.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
Clinical trial summary slide for Nuvalent's ARROS-1 study.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
Includes map of branch locations and three categories of KPIs: scale, profitability, and franchise strength.Old Second Bancorp | Shareholder Engagement Presentation Deck | 25 slides · Old Second Bancorp
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
Includes non-GAAP financial measure disclosures.Old Second Bancorp | Shareholder Engagement Presentation Deck | 25 slides · Old Second Bancorp
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
The slide uses a grid layout to group metrics into three categories: Premier Deposit Franchise, Well-Positioned Balance Sheet, and Strong Financial Performance.Old Second Bancorp | Shareholder Engagement Presentation Deck | 25 slides · Old Second Bancorp
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The chart highlights OSBC's superior performance (127.6%) compared to the community bank group (19.4%).Old Second Bancorp | Shareholder Engagement Presentation Deck | 25 slides · Old Second Bancorp
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a combination of bulleted lists, a comparison table, and a bar chart to demonstrate market momentum.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · AttentionLoop · Cost Of Inaction1 hit
06
Uses two pie charts to illustrate growth over time.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
07
Includes footnotes defining active partners and active programs.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
08
The slide highlights social proof and market validation through a curated list of industry-leading partners.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
09
The chart shows a steady upward trend in clinical programs, with the final bar representing Q1 2023.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
10
OmniAb | Investor Presentation Deck | 39 slidesOmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
05
The chart shows a steady upward trend in the number of active partners, with a CAGR of 18% from 2016 to 2022.OmniAb | Results Presentation Deck | 17 slides · OmniAb
Conference presentation Investor relations Beat · What IsLoop · Cost Of Inaction1 hit
06
The bar chart shows growth from 2016 to 3/31/2023. The pie chart shows the distribution of the 301 active programs.OmniAb | Results Presentation Deck | 17 slides · OmniAb
Conference presentation Investor relations Beat · What IsLoop · Cost Of Inaction1 hit